Balance awarded innovation funding to rollout app to patients

Funding will see balance working with three primary care networks in Greater Manchester.

The balance menopause support app has been awarded £20,000 of funding to research the healtheconomic value of rolling out the app across primary care patients in the north west of England.

As well as giving users access to expert advice, balance also allows women to track their symptoms and download a personalised health report© that they can take to their GPs, helping them receive treatment quicker.

As part of a project to bring new innovations into the Greater Manchester health and social care system, balance will use the funding to implement our award-winning app across three primary care networks in Manchester.

Primary care networks typically serve 30,000 to 50,000 patients and are built on existing primary care services and aim to provide proactive, personalised, coordinated and more integrated health and social care for people close to home.

Our award was given as part of the Research and Innovation (R&I) Health Accelerator, an ERDF (European Regional Development Fund) part-funded project delivered by Health Innovation Manchester, The University of Manchester, The University of Manchester Innovation Factory, Manchester City Council and Bionow.

Gaele Lalahy, balance chief operating officer, said: ‘We are absolutely thrilled to be a successful awardee of the ERDF R&I Accelerator.

‘The funding is enabling us to understand the added value of using the balance menopause app in Manchester primary care pathways. We believe that it will make significant financial savings across the system, free-up scarce resources and allow women to not only better manage their menopausal symptoms but also access the right care and treatment in a timely way.’

Balance was one of five organisations to be awarded funding. The companies were selected by a panel of representatives from Health Innovation Manchester, the Christabel Pankhurst Institute and the University of Manchester Innovation Factory.